
PUSHING THE BOUNDARIES OF WHAT'S POSSIBLE IN MEDICINE
Our platform technology
NewcelX has developed ground-breaking medical applications in regenerative medicine- “off the shelf” cell products. Cell therapy is a new frontier in treating degenerative diseases by replacing, restoring, or repairing malfunctioning cells with healthy, functional cells.
Type 1 Diabetes represents NewcelX’s primary therapeutic focus, and the Company is directing significant scientific and development resources toward advancing cell-based solutions in this area. NewcelX is proud to introduce our differentiation platform technology, insulin secreting islets (IsletRx), which are comprised of highly purified functional human pancreatic islet cells. IsletRx cells have demonstrated an ability to balance blood sugar levels and maintain normal levels over time, as our main candidate for the potential cure of Type 1 Diabetes.
NewcelX has a unique technology that enables the production of functioning cells differentiated from pluripotent stem cells. The Company can transplant healthy brain glial cells (Astrocytes) to support the survivability of nerve cells using AstroRx®, with clinical trials showing promising results in treating ALS.
NewcelX has FDA Approval of its IND Application For its US Multi-Site Phase IIa Clinical Trial of AstroRx® to Treat ALS
NewcelX also introduces its DOXA platform, an innovative multitarget approach to the treatment of central nervous system (CNS) disorders by addressing key neurophysiological pathways beyond traditional symptomatic management.
Unlike conventional therapies that primarily focus on alleviating symptoms, DOXA compounds aim to restore orexin signalling while concurrently modulating neuroinflammatory and metabolic pathways.
This unique approach combines dual orexin receptor activation (OX1R and OX2R) with cathepsin inhibition, offering a comprehensive therapeutic strategy for disorders such as narcolepsy, ALS, and diabetes-related cognitive impairments. Extensive preclinical research supports the potential of DOXA to provide both symptomatic relief and disease-modifying effects.

